Antibody Library Display on a Mammalian Virus: Combining the Advantages of Panning and Cell Sorting in One Technology
Date: | 15-Oct-14 to 15-Oct-14 |
Location: | 82MERCER / Boston / Massachusetts / United States |
Category: | Healthcare & Pharmaceuticals Conferences & Trade Fairs |
Webinar Description:
The course topic is a novel antibody selection technology developed by Vaccinex. The technology enables efficient expression of a library of human antibodies in full length IgG format on the surface of vaccinia virus, an enveloped mammalian virus. This technology combines the advantages of virus panning (high throughput), with the advantages of cell sorting (fine tuning of specificity and affinity). The Vaccinia Display technology enables rapid screening of billions of antibody combinations, with the resulting selection of panels of high affinity antibodies. Importantly, with this technology there is a built in selection for antibodies that pass mammalian cell quality control, ensuring that the selected antibodies are efficiently expressed and have favorable developability properties that are well suited for downstream development.
Learning Objectives:
Attendees should learn that in vitro selection of full length IgG produced in mammalian cells and displayed on virus is superior to competing platform such as phage, yeast and mice.
Attendees should walk away feeling confident that Vaccinex can meet their selection needs from a quality, quantity and timing standpoint.
The course topic is a novel antibody selection technology developed by Vaccinex. The technology enables efficient expression of a library of human antibodies in full length IgG format on the surface of vaccinia virus, an enveloped mammalian virus. This technology combines the advantages of virus panning (high throughput), with the advantages of cell sorting (fine tuning of specificity and affinity). The Vaccinia Display technology enables rapid screening of billions of antibody combinations, with the resulting selection of panels of high affinity antibodies. Importantly, with this technology there is a built in selection for antibodies that pass mammalian cell quality control, ensuring that the selected antibodies are efficiently expressed and have favorable developability properties that are well suited for downstream development.
Learning Objectives:
Attendees should learn that in vitro selection of full length IgG produced in mammalian cells and displayed on virus is superior to competing platform such as phage, yeast and mice.
Attendees should walk away feeling confident that Vaccinex can meet their selection needs from a quality, quantity and timing standpoint.
Visitors
Ernest S. Smith, PhD
Sr Vice President, Research & Chief Scientific Officer
Vaccinex, Inc.
Sr Vice President, Research & Chief Scientific Officer
Vaccinex, Inc.
Exhibitors
Ernest S. Smith, PhD
Sr Vice President, Research & Chief Scientific Officer
Vaccinex, Inc.
Sr Vice President, Research & Chief Scientific Officer
Vaccinex, Inc.
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Breast Cancer News Today
- Breastfeeding News Today
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- SARS News Today
- Wellness News Today